Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
manilatimes8h
Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting
The EFTISARC-NEO trial, with a data cut-off of 20 October 2024, also showed 71.4% of patients achieved a pathologic response ...
Galecto Reports Third Quarter 2024 Financial Results
Third Quarter 2024 Financial Results Cash, cash equivalents, and investments as of September 30, 2024, were approximately $19.7 million. The Company anticipates that its cash, cash equivalents and ...
Cure Today5h
Addressing Pros and Cons of CAR-T Cell Therapy in Melanoma
The advantages and disadvantages of CAR-T cell therapy should be carefully thought about for patients with melanoma.